PROF

Profound Medical Corp. (NASDAQ:PROF) is a Canadian commercial-stage medical device company founded in 2008 and headquartered in Mississauga, Ontario. The company went public on NASDAQ in October 2019, following earlier listings on the Toronto Stock Exchange. Profound Medical specializes in developing and commercializing magnetic resonance-guided ablation procedures for treating various medical conditions, with its primary focus on prostate diseases, uterine fibroids, and palliative pain treatment. The company operates primarily in Canada, the United States, Germany, and Finland, representing a specialized player in the emerging field of MR-guided focused ultrasound therapy.